CELEX: 62011CN0574
Language: en
Date: 2011-11-16 00:00:00
Title: Case C-574/11: Reference for a preliminary ruling from the Landgericht Düsseldorf (Germany), lodged on 16 November 2011 — Novartis AG v Actavis Deutschland GmbH & Co KG, Actavis Ltd.

4.2.2012   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 32/13
            
         Reference for a preliminary ruling from the Landgericht Düsseldorf (Germany), lodged on 16 November 2011 — Novartis AG v Actavis Deutschland GmbH & Co KG, Actavis Ltd.
   (Case C-574/11)
   2012/C 32/24
   Language of the case: German
   
      Referring court
   
   Landgericht Düsseldorf
   
      Parties to the main proceedings
   
   
      Applicant: Novartis AG
   
      Defendants: Actavis Deutschland GmbH & Co KG, Actavis Ltd.
   
      Question referred
   
   Are Articles 4 and 5 of Regulation (EC) No 469/2009 (1) to be interpreted as meaning that the protection conferred by a supplementary protection certificate, which has been granted for a single active ingredient (in this case, Valsartan), extends to a form which contains a combination of active ingredients featuring that single active ingredient (in this case, Valsartan + Hydrochlorothiazide)?
   
      (1)  Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version), OJ 2009 L 152, p. 1.